PURPLEFARM
PURPLEFARM and Curaleaf Laboratories announce UK manufacturing and distribution partnership
Company NewsPublished 3 min read

PURPLEFARM Expands UK Presence Through Partnership with Curaleaf Laboratories

PURPLEFARM announces a manufacturing and distribution agreement with Curaleaf Laboratories, supporting the company's continued development in the UK medical cannabis market.

PURPLEFARM, a Canadian indoor cannabis producer with cultivation facilities in Ontario and New Brunswick, has announced a manufacturing and distribution agreement with Curaleaf Laboratories, a UK manufacturer of cannabis-based medicinal products.

Announced on 17 November 2026, the partnership brings together PURPLEFARM's expertise in genetic selection and controlled indoor cultivation with Curaleaf Laboratories' pharmaceutical manufacturing capabilities and UK distribution network.

Under the agreement, Curaleaf Laboratories will manufacture, package and distribute PURPLEFARM products for the United Kingdom through established, regulated medical channels.

Canadian cultivation meets UK pharmaceutical expertise

PURPLEFARM specialises in indoor cannabis cultivation, genetic selection and quality-focused production. Operating from facilities in Ontario and New Brunswick, the company combines carefully selected genetics with controlled cultivation environments and established post-harvest practices.

Curaleaf Laboratories brings established EU-GMP pharmaceutical manufacturing capabilities, MHRA-compliant facilities and a nationwide distribution network to the partnership.

Together, the companies aim to support a consistent and reliable supply of medical cannabis products for UK healthcare professionals and eligible patients.

The agreement establishes a framework for combining PURPLEFARM's Canadian cultivation expertise with Curaleaf Laboratories' established pharmaceutical manufacturing and distribution infrastructure.

Supporting PURPLEFARM's international growth

The partnership represents another milestone in PURPLEFARM's international development and its strategy of working with established partners in regulated medical cannabis markets.

"Partnering with Curaleaf Laboratories represents an important milestone in our international growth strategy," said Mitchell Alswiti, CEO and Co-Founder of PURPLEFARM, in the official announcement.

The agreement positions PURPLEFARM to continue developing its presence in the UK while working within the country's established pharmaceutical manufacturing, quality assurance and distribution framework.

According to the official announcement, PURPLEFARM products are now available in the United Kingdom through authorised prescribing pathways.

About Curaleaf Laboratories

Curaleaf Laboratories is a UK manufacturer and distributor of cannabis-based medicinal products. The company operates pharmaceutical manufacturing facilities and works within the United Kingdom's regulated medical cannabis framework.

Its manufacturing capabilities, quality management systems and distribution infrastructure support the supply of cannabis-based medicinal products through authorised medical channels.

About PURPLEFARM

PURPLEFARM is a Canadian cannabis producer specialising in indoor cultivation, genetic selection and quality-focused production.

With cultivation facilities in Ontario and New Brunswick, the company develops carefully selected cannabis genetics for regulated domestic and international markets.

PURPLEFARM continues to build its international presence through partnerships with established organisations operating within regulated cannabis markets.

Read the official announcement

The manufacturing and distribution agreement was announced jointly on 17 November 2026, with additional industry coverage published by Business of Cannabis.

UK medical disclaimer

This article is a corporate announcement and is not intended to promote prescription-only medicines to the public. In the UK, cannabis-based medicinal products are available only through applicable authorised prescribing pathways. Treatment decisions should be made by a qualified healthcare professional.